By Karen Roman
REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, said its subretinal treatment of age-related macular degeneration showed improved vision in patients.
Two years of data were published in The Lancet regarding the ongoing trials of ABBV-RGX-314, its potential one-time gene therapy for the treatment of so-called wet AMD.
“We believe that there is multi-billion-dollar potential for ABBV-RGX-314 to become a first-in-class gene therapy for wet AMD and the standard of care to treat and prevent progression of diabetic retinopathy,” said Kenneth T. Mills, REGENXBIO’s President and CEO.
